EN DE
Watch BNC Korea Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BNC Korea Co. Ltd (256840) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of BNC Korea Co. Ltd stock KRW 1,040, price KRW 2,185, that is 52.4% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

BK BNC Korea Co. Ltd logo Thin data Nov 8, 2026

BNC Korea Co. Ltd

256840 · KQ
Very expensive, weak quality

Our calculation puts a fair price 52% below what the stock costs today.

Low debt
Generates free cash flow over the last twelve months
Quality 43/100
Mixed Growth (revenue 5y +37.6 %/yr in KRW)
Loss over the last twelve months · -5.2% net margin (TTM) · fiscal year 2025 3.0%
Fair value 1,040 KRW · Strongly overvalued
3.2% dividend yield · Pays more than it earns
Trails peers (3/12)
Narrow moat 12/100 · thin data
Thin data
Watch BNC Korea Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

55,414 KRW 2,170 KRW Fair Value 1,040 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 2,170 KRW – 55,414 KRW · fair‑value band 960.15 KRW – 1,141 KRW · the 2,185 KRW price screens above the 1,040 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow BNC Korea Co. in your weekly email

Every Wednesday you see whether BNC Korea Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BNC KOREA, Inc. engages in the research and development, production, and sale of biomaterials for medicines in South Korea.

Show moreShow less

The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia.

It also provides HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, Cutegel Hydro, S-DNA, and H-DNA, which are used to temporarily reduce facial wrinkles through physical restoration; Hibarry, a bio-absorbable gel and solution mixture used to prevent adhesion of the spinal cord post-surgery; and GentaQ a beauty face, and home and other care products under the I.st name.

The company was formerly known as BNC Korea Co., Ltd. and changed its name to BNC KOREA, Inc. in April 2026. The company also exports its products to 45 countries. BNC KOREA, Inc. was incorporated in 2007 and is headquartered in Daegu, South Korea.

Stock analysis

BNC Korea Co. Ltd (256840) currently trades at 2,185 KRW, while our model-based Fair Value estimate is 1,040 KRW, 52% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 1,807 KRW per share, and 1 of the 14 models we run sit above the 2,185 KRW price.

Bear case: the Multiples group reads lowest at 808.74 KRW, and 13 of the 14 models stay below the price. Data coverage for this calculation is low.

Scenario range: 960.15 KRW (bear) to 1,141 KRW (bull), the price of 2,185 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

BNC Korea Co. Ltd reported revenue of 95.9B KRW in FY2025 versus 25.2B KRW in FY2021, a compound +39.6%/yr. Reported net income was 2.8B KRW in FY2025.

Key figures

Market cap 149B KRW (≈ $110M) Micro · P/S ratio 1.86 · EPS (TTM) −69.00 KRW · Dividend yield 3.2% · Net margin −5.2% · Return on equity −2.7% · Return on assets (EBIT) −1.4% (5-year average) · Operating margin −3.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 62% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −52%, 256840 screens richer than that median.

Fair Value models

Bear 960.15 KRW Fair Value 1,040 KRW Bull 1,141 KRW
Price 2,185 KRW · Downside -52.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 1,026 KRW 1,040 KRW 1,050 KRW 73
Residual Income 1,688 KRW 1,816 KRW 2,051 KRW 71
ROIC Compounder 1,026 KRW 1,040 KRW 1,050 KRW 71
All 14 models by family
Earnings-Based
Graham-Dodd 282.02 KRW 1,967 KRW 2,760 KRW 63
Lynch FV 737.11 KRW 1,053 KRW 1,369 KRW 61
PEG = 1.0 737.11 KRW 1,053 KRW 1,369 KRW 57
EPV 1,026 KRW 1,040 KRW 1,050 KRW 73
Multiples
P/E Multiple 684.31 KRW 912.42 KRW 1,141 KRW 63
P/S Multiple 528.79 KRW 705.05 KRW 881.31 KRW 57
P/B Multiple 11,014 KRW 14,685 KRW 18,356 KRW 55
EV/EBIT 19.98 KRW 104.26 KRW 188.53 KRW 57
EV/EBITDA 1,341 KRW 1,866 KRW 2,390 KRW 66
EV/Revenue n/a 24.94 KRW >99.76 KRW 49
Asset-Based
NCAV (Graham) 1,192 KRW 1,807 KRW 2,258 KRW 54
Economic Profit
Residual Income 1,688 KRW 1,816 KRW 2,051 KRW 71
ROIC Compounder 1,026 KRW 1,040 KRW 1,050 KRW 71
Growth Earnings
Growth-Adj P/E 960.15 KRW 1,372 KRW 1,783 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 22
How much profit the company makes from its sales and capital
Quality Growth 22
Are margins and returns getting better?
Cashflow 36
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 62
Does it invest with discipline instead of growing at any price?
Low Volatility 28
How calm the share price moves, does not count
Price momentum 12
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 61
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 46/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.6%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.5%
Dividend (yield on the price)3.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 2%

256840 screens overvalued: fair value 52% below the price. Compare with Merck KGaA →

Compare BNC Korea Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Bottom 25%
Fair Value upside −52.4% · Below median
Profitability
Return on assets 1.3% · Below median
Net margin (12 months) −6.6% · Bottom 25%
Operating margin (12 months) −3.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −0.1% · Below median
Dividend yield (12 months) 3.2% · Above median
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.64× · Cheapest 25%
P/S (12 months) 2.10× · Cheaper than median
EV/EBITDA 14.4× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)64 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs 256840
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 256840
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 256840
Haleon plc HLN $9.14 $8.61 −6% vs 256840
Merck KGaA MRK €148.75 €109.18 −27% vs 256840
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 256840
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 256840
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 256840
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 256840
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 256840

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BNC Korea Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BNC Korea Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/256840

Frequently asked questions

Is BNC Korea Co. Ltd (256840) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 1,040 KRW versus a price of 2,185 KRW, about 52% lower (overvalued).
What is the fair value of 256840?
Our model-based fair value for BNC Korea Co. Ltd is 1,040 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 2,185 KRW.
What is the quality score of 256840?
BNC Korea Co. Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BNC Korea Co. Ltd (256840)?
Our model-based price target is the fair value of 1,040 KRW (as of Nov 8, 2026) from 14 valuation models. Cautious scenario 960.15 KRW, optimistic scenario 1,141 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the BNC Korea Co. Ltd stock forecast for 2026?
Our models put fair value at 1,040 KRW, about 52% lower versus a price of 2,185 KRW (overvalued). Cautious scenario 960.15 KRW, optimistic scenario 1,141 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of BNC Korea Co. Ltd (256840)?
BNC Korea Co. Ltd reported trailing-twelve-month revenue of about 91.2B KRW (latest available figure, as of Nov 8, 2026).
Does BNC Korea Co. Ltd pay a dividend?
BNC Korea Co. Ltd currently shows a dividend yield of 3.20% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of BNC Korea Co. Ltd (256840) and when is the ex-dividend date?
BNC Korea Co. Ltd pays a dividend of 70.00 KRW per share a year, a dividend yield of 3.2%. The last ex-dividend date was Dec 29, 2025. The payout ratio is 169% of earnings. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of BNC Korea Co. Ltd (256840)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BNC Korea Co. Ltd it is 1,040 KRW per share (as of Nov 8, 2026), against a price of 2,185 KRW. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is BNC Korea Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 256840 trades above its calculated fair value: price 2,185 KRW, fair value 1,040 KRW, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 256840?
No. The price is what the market pays today (2,185 KRW); the fair value is what the company's own numbers justify (1,040 KRW). For BNC Korea Co. Ltd the two are 1,146 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is BNC Korea Co. Ltd worth?
The market values BNC Korea Co. Ltd at about 149B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 2,185 KRW; our models calculate a fair value of 1,040 KRW per share.
What do the bullish and bearish scenarios say about 256840?
Our models span a range for BNC Korea Co. Ltd: cautious scenario 960.15 KRW, base 1,040 KRW, optimistic 1,141 KRW per share (as of Nov 8, 2026, price 2,185 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BNC Korea Co. Ltd (256840)?
Balance-sheet figures for BNC Korea Co. Ltd (as of Nov 8, 2026): return on equity −2.7%, debt of 0.09 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 256840 from its 52-week high?
BNC Korea Co. Ltd trades at 2,185 KRW, about 62% below its 52-week high of 5,769 KRW and 1% above the low of 2,170 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,040 KRW is for.
Which stocks are comparable to BNC Korea Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BNC Korea Co. Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 2,185 KRW, calculated fair value 1,040 KRW (−52%), Quality Score 43/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 256840 calculated?
We run BNC Korea Co. Ltd through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1,040 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BNC Korea Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BNC Korea Co. Ltd (256840)?
The closing price on Nov 6, 2026 was 2,185 KRW. Our model-based fair value is 1,040 KRW, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BNC Korea Co. Ltd right now?
The price sits above even our optimistic bull case (1,141 KRW). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of BNC Korea Co. Ltd

How large is the market capitalisation of BNC Korea Co. Ltd (256840)?
The market capitalisation of BNC Korea Co. Ltd is 149B KRW (≈ $110M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BNC Korea Co. Ltd (256840)?
The price-to-sales ratio of BNC Korea Co. Ltd is 1.86 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BNC Korea Co. Ltd (256840)?
Earnings per share at BNC Korea Co. Ltd are −69.00 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BNC Korea Co. Ltd (256840)?
The dividend yield of BNC Korea Co. Ltd is 3.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BNC Korea Co. Ltd (256840)?
The net margin of BNC Korea Co. Ltd is −5.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BNC Korea Co. Ltd (256840)?
The return on equity (ROE) of BNC Korea Co. Ltd is −2.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BNC Korea Co. Ltd (256840)?
On an EBIT basis the return on assets of BNC Korea Co. Ltd is −1.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BNC Korea Co. Ltd (256840)?
The operating margin of BNC Korea Co. Ltd is −3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BNC Korea Co. Ltd (256840)?
Revenue at BNC Korea Co. Ltd is growing −0.1% versus a year earlier (3y avg +31.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BNC Korea Co. Ltd (256840) generate?
The free cash flow of BNC Korea Co. Ltd is −1.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does BNC Korea Co. Ltd (256840) carry?
The net debt of BNC Korea Co. Ltd is 20.4B KRW (fiscal year 2021). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch BNC Korea Co. Ltd in the live analysis

One click puts BNC Korea Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.